Dietmar Berger
Known title: Chief Medical OfficerCIK: 0001739515
Associated companies
Transaction History
| GILD | ▲ Buy | Option Exercise | 533 | — | 9/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 263 | $38K | 9/10/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 533 | — | 6/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 263 | $32K | 6/10/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,133 | — | 3/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,063 | $158K | 3/10/2026 | View on chart |
| GILD | ▲ Buy | Grant | 8,530 | $0 | 2/27/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 16,326 | — | 1/2/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 6,944 | $844K | 1/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.